Physician profile
Michael Couser
NPI 1891316451
$1,114.49
in general payments reported to CMS, 2019-2025
18 companies · $527 in 2025
The $527 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.30 · 2023: $203 · 2024: $369 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,099.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $166.36 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $162.53 | 2023-2025 | Vraylar |
| Axsome Therapeutics, INC. | $114.03 | 2024-2025 | Auvelity |
| Exact Sciences Corporation | $111.44 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.92 | 2024-2025 | Jardiance, Synjardy |
| Pfizer INC. | $76.08 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $71.83 | 2024-2025 | Caplyta |
| Edwards Lifesciences Corporation | $61.71 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Lilly USA, LLC | $44.10 | 2021-2025 | Zepbound, Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $37.46 | 2023-2025 | Trintellix |
| Inari Medical, INC. | $35.61 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Astrazeneca Pharmaceuticals LP | $27.77 | 2023-2024 | Breztri, Airsupra |
| Gilead Sciences, INC. | $26.01 | 2025 | |
| Vanda Pharmaceuticals INC. | $25.93 | 2025 | Fanapt |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.04 | 2025 | Xifaxan |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $21.97 | 2023 | Quviviq |
| Paratek Pharmaceuticals, INC. | $15.94 | 2025 | Nuzyra |
| Glaxosmithkline, LLC. | $15.76 | 2023 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Couser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.